{"id":"W3017839166","doi":"10.1016/j.jaad.2020.04.104","title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"ca_institutions":"Innovaderm (Canada)","funders":"Samsung Bioepis; Cilag; Maruho; Merck Sharp and Dohme; LEO Pharma; Medac; AbbVie; Glenmark Pharmaceuticals; Fresenius Medical Care North America; Janssen Biotech; Les Laboratories Pierre Fabre; Galápagos; Valeant Pharmaceuticals International; Sun Pharma; School of Public Health, University of California Berkeley; Miltenyi Biotec; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Pfizer; Biogen; Novartis; Celgene; Procter and Gamble; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Almirall; Galderma; Asana Biosciences; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Atopic dermatitis; Medicine; Reliability (semiconductor); Dermatology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001361328,0.0002179261,0.001114527,0.00003055661,0.0003047999,0.00001233797,0.0006904912,0.0001189784,0.000001870594],"category_scores_gemma":[0.005380567,0.0001045966,0.0003863517,0.0002957277,0.001960903,0.00008192349,0.000238872,0.0004930556,1.940728e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001041758,"about_ca_system_score_gemma":0.0008863747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001531577,"about_ca_topic_score_gemma":0.000004026298,"domain_scores_codex":[0.9960881,0.0005158598,0.002329194,0.0001968023,0.0005743143,0.0002957664],"domain_scores_gemma":[0.9934204,0.002642689,0.002996724,0.0002734814,0.000445547,0.0002211634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001713032,0.0002298124,0.983162,0.0006388279,0.0007721757,0.00000326653,0.0003216137,0.00003004927,0.000160375,0.0004399501,0.004559669,0.009510978],"study_design_scores_gemma":[0.002727858,0.0001893081,0.975334,0.0001988888,0.0007239402,0.001199514,0.000688254,0.001945303,0.004357783,0.0008190771,0.01170524,0.0001108462],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8177331,0.0007326445,0.003701304,0.17664,0.0001649971,0.000960044,0.00004614102,0.000007859922,0.00001393007],"genre_scores_gemma":[0.9707522,0.0001238297,0.0200186,0.009004911,0.0000419429,0.00004419079,0.000001146778,0.00001133301,0.000001856606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1676351,"threshold_uncertainty_score":0.7225028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1220590217899888,"score_gpt":0.3860614693203945,"score_spread":0.2640024475304057,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}